Etern Therapeutics to build headquarters in WND

The signing ceremony for Etern's headquarters and the unveiling ceremony of the WND biological and chemical interdisciplinary research achievement transformation platform are held. [Photo/WeChat account: xinwu_wx]

Shanghai-based Etern Therapeutics signed an agreement to locate its headquarters in Wuxi New District on Sep 11th.

As a pioneer in the field of targeted protein liquid-liquid phase separation in China, Etern is renowned for its cutting-edge technology and top-tier research and development team. The company plans to invest 2 billion yuan ($275.14 million) to establish its headquarters in WND and recruit world-class talent from prestigious institutions to create a research platform.

Unveiled alongside this project was the WND biological and chemical interdisciplinary research achievement transformation platform, which is designed to gather a diverse array of innovative resources and facilitate efficient collaboration among government, industry, academia, and research institutions.

WND is the core of Wuxi's biopharmaceutical industry, boasting a total of 420 biopharmaceutical enterprises which account for 53.6 percent of the city's total output. WND has attracted four global pharmaceutical giants, including AstraZeneca.